Labeling updates & new warnings
FDA notified healthcare professionals and consumers of new safety information regarding taking 5-hydroxy-tryptamine receptor agonists (triptans) and selective serotonin reuptake inhibitors (SSRIs) or selective serotonin/norepinephrine reuptake inhibitors (SNRIs) concomitantly.
FDA notified healthcare professionals and consumers of new safety information regarding taking 5-hydroxy-tryptamine receptor agonists (triptans) and selective serotonin reuptake inhibitors (SSRIs) or selective serotonin/norepinephrine reuptake inhibitors (SNRIs) concomitantly. A life-threatening condition called serotonin syndrome may occur when triptans are used in conjunction with a SSRI or SNRI. Symptoms of serotonin syndrome may include restlessness, hallucinations, loss of coordination, fast heart beat, rapid changes in blood pressure, increased body temperature, overactive reflexes, nausea, vomiting, and diarrhea.
Chief Pharmacy Officer Jason R. Smith on the Challenges Health Systems Face
May 28th 2025Jason R. Smith, Pharm.D., appointed as chief pharmacy officer in February 2025 for the University of Rochester Medical Center, talks about building a stronger workforce, managing drug shortages and keeping up with changes in regulations because of the new administration.
Read More
